You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
眾生藥業(002317.SZ)獲得1項發明專利證書
格隆匯 05-17 20:13

格隆匯5月17日丨眾生藥業(002317.SZ)公佈,近日,公司收到中華人民共和國國家知識產權局頒發的發明專利證書。發明名稱:FGFR4抑制劑及其製備方法和應用。

本專利是公司在抗腫瘤領域佈局的創新藥ZSP1241項目的化合物專利,屬於該項目的核心專利。ZSP1241是公司研發的具有明確作用機制並具有自主知識產權的創新藥物,ZSP1241體內外強效,在多種肝癌、胃癌人源腫瘤細胞系異種移植(CDX)或者人源腫瘤組織來源移植瘤(PDX)模型上展現顯著抗腫瘤作用,且可通過與索拉非尼聯合使用增強療效。目前,用於治療肝癌、胃癌等晚期惡性腫瘤的ZSP1241片正在開展I期臨牀試驗。

ZSP1241項目化合物專利目前已獲得包括中國、歐洲、美國、韓國、加拿大、新西蘭、澳大利亞、南非等國家/地區的專利授權,此次項目核心專利獲得專利授權有利於公司進一步完善知識產權保護體系,發揮自主知識產權優勢,保持技術領先地位。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account